肿瘤局部相关因素对N0期食管癌IMRT预后影响

doi:10.3760/cma.j.issn.1004-4221.2020.02.004

摘要
图/表
参考文献(29)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的探讨食管癌肿瘤局部相关因素对接受根治性放化疗N0期食管鳞癌患者GTV内复发的影响,并分析对10年长期生存的影响。方法对河北医科大学第四医院2005-2010年收治的根治性放化疗临床N0期食管鳞癌患者374例进行回顾分析。284例累及野照射,90例择性淋巴结照射。69l例同期放化疗,38例序贯放化疗。Kaplan-Meier法生存分析,Cox模型多因素预后分析。结果全组患者出现GTV内复发143例(38.2%),GTV内复发者GTV最大横径(GTV-D)、GTV体积(GTV-V)和GTV-体积/长度(GTV-V/L)均显著长于GTV内未失败者(P=0.008、0.043、0.001)。ROC曲线分析结果显示GTV-D、GTV长度(GTV-L)、GTV-V和GTV-V/L判断GTV内复发的最佳诊断阈值分别为3.5cm、5.5cm、24.0cm³和4.6cm²(P=0.000、0.003、0.000、0.000),且其值较大者GTV内复发比率均大于其余组(P=0.000、0.002、0.001、0.000)。GTV-L和GTV-V/L为影响GTV内复发的因素(P=0.021、0.009)。全组3、5、10年生存率分别为42.9%、23.2%和7.9%,多因素分析结果显示年龄、T分期、联合化疗、GTV-D和GTV-V/L为影响生存的因素(P=0.027、0.000、0.018、0.009、0.034)。生存时间≥5年的主要死亡原因仍与肿瘤相关。结论食管癌肿瘤局部相关因素对接受根治性放化疗临床N0食管鳞癌患者GTV内复发有显著影响,可作为GTV内复发的预测指标。GTV-D和GTV-V/L为显著影响患者10年生存的因素。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	沈文斌
	高红梅
	许金蕊
	曹彦坤
	李曙光
	李幼梅
	祝淑钗

关键词 ：食管肿瘤/放化疗法, 原瘤床区复发, 预后

Abstract：Objective To evaluate the effect of locoregional risk factors of esophageal cancer on the recurrence of gross tumor volume (GTV) in patients with N0 esophageal squamous cell carcinoma after radical intensity-modulated radiotherapy (IMRT) and to evaluate its effect on the 10-year survival of patients. Methods Clinical data of 374 patients with clinical N0 esophageal squamous cell carcinoma who underwent radical IMRT in the Fourth Hospital of Hebei Medical University from 2005 to 2010 were retrospectively analyzed. Involved-field irradiation was performed in 284 patients and selective lymph node irradiation was given in 90 patients. Concurrent radiochemotherapy was conducted in 69l patients and sequential radiochemotherapy was performed in 38 patients. The survival analysis was carried out by Kaplan-Meier method. The prognosis analysis was performed by multivariate Cox’s regression model. Results A total of 143 patients (38.2%) had recurrence in GTV. The maximum transverse diameter (GTV-D),GTV volume (GTV-V) and GTV volume/length (GTV-V/L) of GTV patients were significantly longer than those without recurrence in GTV (P=0.008,0.043,0.001). ROC curve analysis showed that the optimal diagnostic thresholds for GTV-D,GTV-L,GTV-V and GTV-V/L for GTV recurrence were 3.5 cm,5.5 cm,24.0 cm³ and 4.6 cm²,respectively (P=0.000,0.003,0.000 and 0.000),and the ratio of recurrence within GTV in the patient group was significantly greater than that in the smaller group (P=0.000,0.002,0.001 and 0.000). GTV-L and GTV-V/L were the independent risk factors of recurrence in GTV (P=0.021 and 0.009). The 3-, 5-and 10-year survival rates of all patients in the whole group were 42.9%, 23.2% and 7.9%, respectively. Multivariate analysis demonstrated that age, T stage, concurrent radiochemotherapy, GTV-D and GTV-V/L were the independent risk factors of survival (P=0.027, 0.000, 0.018, 0.009 and 0.034). The main cause of death in patients with a survival time of more than 5 years was still associated with cancer. Conclusions The locoregional risk factors of esophageal cancer exert significant effect on the recurrence of GTV in patients with N0 esophageal squamous cell carcinoma undergoing radical radiochemotherapy, which can be utilized as the predicting markers. Both GTV-D and GTV-V/L are significantly correlated the 10-year survival of patients.

Key words： Esophageal neoplasm/radiochemotherapy Recurrence of primary tumor bed Prognosis

收稿日期: 2019-05-05

通讯作者: 祝淑钗,Email:sczhu1965@163.com

引用本文:

沈文斌,高红梅,许金蕊等. 肿瘤局部相关因素对N0期食管癌IMRT预后影响[J]. 中华放射肿瘤学杂志, 2020, 29(2): 96-101.

Shen Wenbin,Gao Hongmei,Xu Jinrui et al. Effect of locoregional risk factors on long-term prognosis of patients with N0 stage esophageal cancer receiving intensity-modulated radiotherapy[J]. Chinese Journal of Radiation Oncology, 2020, 29(2): 96-101.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2020.02.004 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2020/V29/I2/96

[1] Bray F,Ferlay J,Soeriomataram I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality world wide for 36 cancers in185 countries[J]. CA Cancer J Clin,2018,68(6):394-424. DOI:10.3322/caac.21492.
[2] Xia L,Zheng R,Xu Y,et al. Incidence and mortality of primary bone cancers in China,2014[J]. Chin J Cancer Res,2018,30(1):1-12. DOI:10.21147/j.issn.1000-9604.2018.01.01.
[3] Huang J,Mo H,Zhang W,et al. Promising efficacy of SHR-1210,a novel anti-programmed cell death 1 antibody,in patients with advanced gastric and gaetroesophageal junction cancer in China[J]. Cancer,2019,125(5):742-749. DOI:10.1002/cncr:31855.
[4] Fuchs CS,Doi T,Jang RW,et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer:phase 2 clinical KEYNOTE-059 trial[J]. JAMA Oncol,2018,4(5):e180013. DOI:10.1001/jamaoncol.2018.0013.
[5] Suntharalingam M,Winter K,Ilson D,et al. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial[J]. JAMA Oncol,2017,3(11):1520-1528. DOI:10.1001/jamaoncol.2017.1598.
[6] Mimura K,Yamada L,Ujiie D,et al. Immunotherapy for esophageal squamous cell carcinoma:a review[J]. Fukushima J Med Sci,2018,64(2):46-53. DOI:10.5387/fms.2018-09.
[7] Zeng H,Chen W,Zheng R,et al. Changing cancer survival in China during 2003-15:apooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health,2018,6(5):e555-e567. DOI:10.1016/S2214-109X (18)30127-X.
[8] Pennathur A,Gibson MK,Jobe BA,et al. Oesophageal carcinoma[J]. Lancet,2013,381(9864):400-412. DOI:10.1016/S0140-6736(12)60643-6.
[9] Sjoquist KM,Burmeister BH,Smithers BM,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis[J]. Lancet Oncol,2011,12(7):681-692. DOI:10.1016/S1470-2045(11)70142-5.
[10] Versteijne E,van Laarhoven HW,van Hooft JE,et al. Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer:locoregional recurrence pattern[J]. Dis Esophagus,2015,28(5):453-459. DOI:10.1111/dote.12215.
[11] Kosugi S,Ichikawa H,Kanda T,et al. Clinicopathological characteristics and prognosis of patients with esophageal carcinoma invading adjacent structures found during esophagectomy[J]. J Surg Oncol,2012,105(8):767-772. DOI:10.1002/jso.22092.
[12] 中国非手术治疗食管癌临床分期专家小组. 非手术治疗食管癌的临床分期标准(草案)[J]. 中华放射肿瘤学杂志,2010,19(3):179-180. Doi:10.3760/cma.j.issn.1004-4221.2010.03.001.
Expert group on clinical staging of esophageal cancer in China. Clinical staging criteria for non-surgical treatment of esophageal cancer (Draft)[J]. Chin J Radiat Oncol, 2010,19(3):179-180.
[13] Picus D,BalleDM,Koehlet RE,et al. Computed tomography in the staging of esophageal carcinoma[J]. Radiology,1983,146(2):433. DOI:10.1148/radiology.146.2.6849089.
[14] Thompson WM,Halvorsen RA,Foster WL Jr,et al.Computed tomography for staging esophageal and gastroesophageal cancer:reevaluation[J]. AJR Am J Roentgenol,1983,141(5):951-958. DOI:10.2214/ajr.141.5.951.
[15] Wong RKS,Malthaner R. Combined chemotheraphy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma uf the esophagus[J]. Cochrane Databse Syst Rev,2006(1):CD002092. DOI:10.1002/14651858. CD002092.pub2.
[16] Kachnic LA,Winter K,Wasserman T,et al. Longitudinal quality-of-life analysis of RTOG 94-05(Int 0123):a phase Ⅲ trial of definitive chemoradiotherapy for esophageal cancer[J]. Gastroint Cancer Res,2011,4(2):45-52.
[17] Lin SH,Wang L,Myles B,el a1. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy for esophageal cancer[J]. Int J Radiat Oncol Biol Phys,2012,84(5):1078-1085. DOI:10.1016/j.ijrobp.2012.02.015.
[18] Lee CC,Chu ST,Ho HC,et al.Primary tumor volume calculation as a predictive factor of prognosis in nasopharyngeal carcinoma[J]. Acta Oto-Laryngologica,2008,128(1):93-97. DOI:10.1080/00016480701361921.
[19] Kim HW,Kim JH,Lee IJ,et al. Local control may be the key in improving treatment outcomes of esophageal squamous cell carcinoma undergoing concurrent chemoradiation[J]. Digestion,2014,90(4):254-260. DOI:10.1159/000368983.
[20] Welsh J,Settle SH,Amini A,et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation[J]. Cancer,2012,118(10):2632-2640. DOI:10.1002/cncr.26586.
[21] 曾静,庞青松,章文成,等. 食管癌根治性调强放疗大体肿瘤体积因素与靶区内放疗失败的关系[J]. 中华放射肿瘤学杂志,2019,28(2):85-89. DOI:10.3760/cma. J.issn.1004-4221.2019.02.002. Ceng Jing,Pang Qingsong,Zhang Wencheng,et al. Relationship between factors of gross tumor volume and locoregional failure of radical intensity-modulated radiation therapy for esophageal carcinoma[J]. Chin J Radiat Oncol, 2019,28(2):85-89.
[22] 高红梅,沈文斌,池书平,等. CT测量食管癌体积与预后的相关性[J]. 中国医学影像学杂志,2014,22(3):172-176. DOI:10.3969/j.issn.1005-5185.2014.03.004.
Gao Hongmei,Shen Wenbin,Chi Shuping,et al. CT Volumetry of Esophageal Carcinoma and Its Correlation with Prognosis[J]. Chinese Journal of Medical Imaging, 2014,22(3):172-176.
[23] Iizuka T,Isono K,Kakegawa T,et al. Parameters linked to ten-year survival in Japan of resected esophageal carcinoma[J]. Chest,1989,96(5):1005-1011. DOI:10.1378/chest.96.5.1005.
[24] Chen CZ,Chen JZ,Li DR,et al.Long-term outcomes and prognostic factors for patients with esophageal cancer following radiotherapy[J]. World J Gastroenterol,2013,19(10):1639-1644. DOI:10.3748/wjg.v19.i10.1639.
[25] 高红梅,时高峰,韩楚源,等. 不同检测方法测量食管病变长度的对比分析[J]. 实用放射学杂志,2012,28(7):1116-1119. DOI:10.3969/j.issn.1002-1671.2012.07.035.
Gao Hongmei,Shi Gaofeng,Han Chuyuan,et al. Compartive analyses on measurement of the length of esophageal carcinoma with different detecting methods[J]. J Pract Radiol,2012,28(7):1116-1119.
[26] 王军,祝淑钗,韩春,等. CT扫描食管造影和内窥镜测量食管癌病变长度的价值[J]. 中国肿瘤临床,2008,35(17):967-970.
Wang Jun,Zhu Shuchai,Han Chun,et al. TheValue of CT Scan,Esophagogram and Endoscopy in De6ning the Length of Esophageal Carcinoma[J]. Clinical oncology in China, 2008,35(17):967-970.
[27] Lyu J,Gan H,Zhang W,et al. Relative tumor volume is a better independent prognostic factor in esophageal squamous cell carcinoma:Results of a retrospective study[J]. Med (Baltimore),2019,98(14):e14963. DOI:10.1097/MD.0000000000014963.
[28] Chen M,Li X,Chen Y,et al. Proposed revision of the 8^th edition AJCC clinical staging system for esophageal squamous cell cancer treated with definitive chemo-IMRT based on CT imaging[J]. Radiat Oncol,2019,14(1):54. DOI:10.1186/s13014-019-1258-4.
[29] Miyamoto H,Kunisaki C,Sato S,et al. Tumor volume index as a prognostic factor in patients after curative esophageal cancer resection[J]. Ann Surg Oncol,2019,26(6):1909-1915. DOI:10.1245/s10434-019-07308-9.